Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2004

View Archived Issues

Novel small molecule with thrombopoietin mimetic activity

Potent PARP inhibitor improves cardiac and endothelial dysfunction

Bivalent mu-kappa opioid receptor ligand attenuates morphine tolerance

Combined immunostimulatory treatment enhances antitumor activity in vivo

New approach to cardiovascular diseases by targeting NFkappaB

Curcuma longa shows cardioprotective effects in vivo

Yentreve approved in E.U. for stress urinary incontinence

King and Palatin to jointly develop, commercialize PT-141

Genelabs completes Prestara study

AMG-162 pivotal study triggers milestone payment to Abgenix

Swiss approval for Femara as extended adjuvant treatment

New phase II study for HuMax-CD4 in non-cutaneous T-cell lymphoma

Three series of chemokine CCR5 modulators claimed by AstraZeneca

Selective neutral endopeptidase inhibitors reported by Pfizer scientists

Novel oxazolidinone-based antibacterial agents under study at AstraZeneca

Alpharma presents new 10-modified erythromycins and their use as antibacterial agents

New HSP90 inhibitors and their use in cancer and other disorders

New TACE inhibitors and their use covered by Vertex patent

FDA and Genentech issue warning on Avastin

Cangene plans new anthrax project

Medinox and PUMC to develop NOX-100 in China and South Korea

Positive opinion for reimbursement of Advate in France

MorphoSys and Boehringer Ingelheim initiate new antibody program

European approval for higher dosage of candesartan cilexetil

Amgen completes acquisition of Tularik

Yamanouchi and Boehringer Ingelheim to copromote Flomax in U.S. for BPH

Discovery of potent himbacine-based thrombin receptor antagonist

Abbott presents new Bcl-targeting agents with potential in cancer chemotherapy

Improved histamine H3 antagonists/inverse agonists presented by Abbott

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...